Alpha 2.0
Login Register
» Articles » PMID: 35994416

Identification of a Circulating Immunological Signature Predictive of Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

Overview
Journal Clin Transl Med
Publisher Wiley
Specialty General Medicine
Date 2022 Aug 22
PMID 35994416
Authors
Wassila Khatir
Olivier Humbert
Jonathan Benzaquen
Christophe Bontoux
Jaap Neels
Lea Berland
Fabian Andres Gallardo Rivera
Maryline Allegra
Myriam Salah
Virginie Tanga
Olivier Bordone
Julien Fayada
Virginie Lespinet-Fabre
Doriane Bohly
Elodie Long-Mira
Sandra Lassalle
Valerie Vouret
Patrick Brest
Baharia Mograbi
Charlotte Maniel
Josiane Otto
Jacques Boutros
Simon Heeke
Veronique Hofman
Charles-Hugo Marquette
Paul Hofman
Marius Ilie
Affiliations
Soon will be listed here.
Citing Articles

Plasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy Initiation.

Janho Dit Hreich S, Humbert O, Pace-Loscos T, Schiappa R, Juhel T, Ilie M Cancers (Basel). 2024; 16(12).

PMID: 38927931 PMC: 11202099. DOI: 10.3390/cancers16122226.

The Need to Set up a Biobank Dedicated to Lymphoid Malignancies: Experience of a Single Center (Laboratory of Clinical and Experimental Pathology, University Côte d'Azur, Nice, France).

Bontoux C, Marcovich A, Goffinet S, Pesce F, Tanga V, Bohly D J Pers Med. 2023; 13(7).

PMID: 37511690 PMC: 10381579. DOI: 10.3390/jpm13071076.

Matched tissue and liquid biopsies for advanced non-small cell lung cancer patients A potentially indispensable complementary approach.

Hofman P Transl Oncol. 2023; 35:101735.

PMID: 37413719 PMC: 10366644. DOI: 10.1016/j.tranon.2023.101735.

Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and challenges.

Parra E, Ilie M, Wistuba I, Hofman P Br J Cancer. 2023; 129(9):1417-1431.

PMID: 37391504 PMC: 10628288. DOI: 10.1038/s41416-023-02318-7.

References
1.
Morad G, Helmink B, Sharma P, Wargo J . Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021; 184(21):5309-5337. PMC: 8767569. DOI: 10.1016/j.cell.2021.09.020. View
2.
Goc J, Lv M, Bessman N, Flamar A, Sahota S, Suzuki H . Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer. Cell. 2021; 184(19):5015-5030.e16. PMC: 8454863. DOI: 10.1016/j.cell.2021.07.029. View
3.
Garon E, Hellmann M, Rizvi N, Carcereny E, Leighl N, Ahn M . Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019; 37(28):2518-2527. PMC: 6768611. DOI: 10.1200/JCO.19.00934. View
4.
Sanmamed M, Nie X, Desai S, Villaroel-Espindola F, Badri T, Zhao D . A Burned-Out CD8 T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. Cancer Discov. 2021; 11(7):1700-1715. PMC: 9421941. DOI: 10.1158/2159-8290.CD-20-0962. View
5.
Becht E, Giraldo N, Germain C, De Reynies A, Laurent-Puig P, Zucman-Rossi J . Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Adv Immunol. 2016; 130:95-190. DOI: 10.1016/bs.ai.2015.12.002. View